China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
NEW YORK and MELBOURNE, Australia, Feb. 24, 2017 -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the second quarter/half year ended December 31, 2016 and provide a corporate update beginning at 5:00 pm Eastern Standard Time on Sunday, February 26, 2017 and 9:00 am Australian Eastern Daylight Time on Monday, February 27, 2017.
To access the call, dial 1 855 881 1339 (US), 1 800 558 698 (toll-free Australia) or +61 2 9007 3187 (outside of the US and Australia).
The conference identification code is 638112.
The live webcast can be accessed via:
http://webcasting.boardroom.media/broadcast/58af4d2b196ffa2970ec979c
The conference call will be accompanied by a slide presentation. Please log in approximately 15 minutes prior to the scheduled start time.
The archived webcast will be available in the Events and Presentations section of the Investor page on the Company’s website – www.mesoblast.com
About Mesoblast
Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular diseases, immune-mediated and inflammatory disorders, orthopedic disorders, and oncologic/hematologic conditions.
For further information, please contact: Julie Meldrum Global Head, Corporate Communications Mesoblast Limited T: +61 3 9639 6036 E: [email protected] Schond Greenway VP, Investor Relations Mesoblast Limited T: +1 212 880-2060 E: [email protected]
